NSCLC Stage IVPhase 1/2NCT05950139
Peptide vaccine
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
98 studies recruiting right now, most recently updated first.
Open the Phase 2 page · a list of only those studies
Triangle is made by Triangle Health, Inc.
Lung and thoracic98 studies
NSCLC Stage IVPhase 1/2NCT05950139
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
Lung Non-Small Cell CarcinomaФаза 2NCT05242965
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Sargramostim, Computed Tomography, Biopsy
Small Cell Lung CarcinomaФаза 2NCT05882058
BI 764532, dose 1, BI 764532, dose 2, Ventana DLL3 RxDx assay
Non-Small Cell Lung CancerPhase 1/2NCT06088771
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
Lung Cancer (NSCLC)Фаза 2NCT07405190
Ivonescimab, carboplatin, pemetrexed
Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Фаза 2NCT07452224
ILKN421H, Pembrolizumab
Untreated Stage IV or Recurrent Non-Small Cell Lung CancerPhase 1/2NCT07355205
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Extensive Stage Lung Small Cell CarcinomaФаза 2NCT07423585
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test
Locally Advanced Lung Non-Small Cell CarcinomaPhase 1NCT05136846
Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer
Metastatic Non Small Cell Lung CancerФаза 2NCT04614103
LN-145
Lung Non-Small Cell CarcinomaPhase 1NCT06225427Papers
Gilteritinib for the Treatment of ALK NSCLC
Metastatic Lung Non-Small Cell CarcinomaФаза 2NCT05570825
Biopsy, Biospecimen Collection, Computed Tomography, CXCR1/2 Inhibitor SX-682
Non-Small Cell Lung CancerФаза 2NCT07603856
Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab), Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments), Ablative Hypofractionated Radiotherapy
Non Small Cell Lung CancerФаза 2NCT06364917
Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed
Lung CancerФаза 2NCT05419076
Stereotactic Radiosurgery, Cerebrospinal fluid collection
Non-small Cell Lung CancerФаза 2NCT04332367
Carboplatin, Paclitaxel, Ramucirumab
Locally Advanced or Metastatic Non-Small Cell Lung Cancer (ECOG 2)Phase 1NCT04297605
Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
Relapsed/Refractory Small Cell Lung CancerPhase 1NCT07249879
This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer
Non-Small Cell Lung Cancer With Brain MetastasesPhase 1/2NCT07535463
Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer
ALK-Positive Lung Cancer With Brain MetastasesPhase 1/2NCT05987644
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
Malignant Pleural EffusionPhase 1NCT07443020
Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors
Advanced EGFR-Mutant Non-Small Cell Lung CancerPhase 1NCT04762199
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
Metastatic Non-Small Cell Lung CancerPhase 1NCT05452005
Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer
Metastatic Lung Non-Small Cell CarcinomaPhase 1NCT05234307
PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer